Business Description
Atreca Inc
NAICS : 325412
SIC : 2834
ISIN : US04965G1094
Share Class Description:
FRA:0C1: Class ADescription
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.7 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 17.5 | |||||
| 3-Year EPS without NRI Growth Rate | 16.1 | |||||
| 3-Year FCF Growth Rate | 18.6 | |||||
| 3-Year Book Growth Rate | -33 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.46 | |||||
| 9-Day RSI | 27.9 | |||||
| 14-Day RSI | 30.01 | |||||
| 6-1 Month Momentum % | -70.38 | |||||
| 12-1 Month Momentum % | -78.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | |||||
| Quick Ratio | 1.58 | |||||
| Cash Ratio | 1.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.8 | |||||
| Shareholder Yield % | 469.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -167.93 | |||||
| ROA % | -81.07 | |||||
| ROIC % | -116.14 | |||||
| ROC (Joel Greenblatt) % | -131.08 | |||||
| ROCE % | -72.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.35 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | 0.21 | |||||
| EV-to-Forward-EBIT | -0.44 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-Forward-EBITDA | -0.44 | |||||
| EV-to-Forward-Revenue | 9.7 | |||||
| EV-to-FCF | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 0.44 | |||||
| Price-to-Net-Cash | 0.62 | |||||
| Earnings Yield (Greenblatt) % | 476.19 | |||||
| FCF Yield % | -1714.34 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers